Alnylam provides long-term look at Oxlumo, aiming to further carve out stake in PH1 market

As part of continuing analyses from its randomized, placebo-controlled Phase III trial for Oxlumo (lumasiran), Alnylam reported positive 12-month follow-up data in trial participants with primary hyperoxaluria type 1. New results have shown the drug was associated with improving calcium deposit levels in one or both kidneys, or nephrocalcinosis, relative to baseline.